Nav: Home

UTHealth's Wolinsky is senior author of paper on new therapy for primary MS

December 21, 2016

HOUSTON - (Dec. 21, 2016) - Positive results of an investigational medication study for primary progressive multiple sclerosis were published online in today's New England Journal of Medicine in a paper led by senior author Jerry Wolinsky, M.D., of McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth).

The study, called ORATORIO, was one of three published in the journal about the medication ocrelizumab (OCREVUS®), which was designed to target immune cells called CD20-positive B cells that contribute to myelin and axonal nerve damage. That damage can lead to disability in people with multiple sclerosis (MS).

Wolinsky, now emeritus professor of neurology at McGovern Medical School at UTHealth, was director of the Multiple Sclerosis Research Group at UTHealth at the time of the study

"Understanding what drives disability in the progressive phases of MS has been one of my focuses over the last several decades," Wolinsky said. "We are finally showing that applying highly effective anti-inflammatory therapies that substantially limit new lesion formation makes a clinical difference in primary progressive MS. This not only opens this anti-B cell therapy as a proven approach for our patients, it also should serve to redouble our efforts to find novel agents to limit tissue damage as well as attempts to facilitate repair. We have made great strides, but much work remains to be done."

Wolinsky was a co-author of a second paper published today in the journal that detailed positive results of two other studies, OPERA I and OPERA II. In those studies, ocrelizumab was compared with interferon beta-1a for patients with relapsing MS, the most common form of the disease.

MS occurs when the immune system abnormally attacks the insulation and support around nerve cells (myelin sheath) in the brain, spinal cord and optic nerves, causing inflammation and consequent damage. This damage can cause a wide range of symptoms, including muscle weakness, fatigue and difficulty seeing, and may eventually lead to disability.

Most people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of non-traumatic disability in younger adults.

Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms, but typically without distinct relapses or periods of remission. Approximately 10-15 percent of people with MS are diagnosed with the primary progressive form of the disease.

There are no approved treatments for PPMS. Results of the phase 3 trial, which compared ocrelizumab with placebo, showed a reduction in the progression of clinical disability, which was sustained for 12 weeks. The secondary endpoints in all three studies were also met, including multiple measures of disability progression and brain lesion activity.

During ORATORIO, 732 patients either received intravenous infusions of OCREVUS or placebo. In contrast to the OPERA I and OPERA II studies, where the blinded treatment period was two years, the blinded treatment period of the ORATORIO study continued beyond that until all patients had received at least 120 weeks of either OCREVUS or placebo and a predefined number of confirmed disability progression events was reached overall in the study.
-end-


University of Texas Health Science Center at Houston

Related Multiple Sclerosis Articles:

New biomarkers of multiple sclerosis pathogenesis
Multiple sclerosis (MS) is a chronic debilitating inflammatory disease targeting the brain.
Using telemedicine to treat multiple sclerosis
Multiple sclerosis (MS) clinicians face continued challenges in optimizing neurological care, especially for people with advanced MS living in medically underserved communities.
Improving symptom tracking in multiple sclerosis
With a recent two-year, $833,000 grant from the US Department of Defense, kinesiology professor Richard van Emmerik and colleagues at the University of Massachusetts Amherst hope to eventually help an estimated 1 million people worldwide living with progressive multiple sclerosis by creating an improved diagnostic test for this form of the disease, which is characterized by a steady decrease in nervous system function.
An antibody-based drug for multiple sclerosis
Inserm Unit U919, directed by Professor Denis Vivien has developed an antibody with potential therapeutic effects against multiple sclerosis.
Four new risk genes associated with multiple sclerosis discovered
Scientists of the Technical University of Munich and the Max Planck Institute of Psychiatry have identified four new risk genes that are altered in German patients with multiple sclerosis.
PET detects neuroinflammation in multiple sclerosis
The triggers of autoimmune inflammation in multiple sclerosis (MS) have eluded scientists for many years, but molecular imaging is bringing researchers closer to identifying them, while providing a means of evaluating next-generation therapies for MS, say researchers introducing a study at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging.
Scientists find genetic cause of multiple sclerosis
Researchers have discovered a rare genetic mutation that makes it probable that a person will develop multiple sclerosis (MS).
ANKRD55: A new gene involved in Multiple Sclerosis is discovered
The Ikerbasque researcher Koen Vandenbroeck, who heads the Neurogenomiks laboratory which reports to the Achucarro centre and the UPV/EHU-University of the Basque Country, together with other national and international groups, has shown that a genetic variant in the 5q11 chromosome, which is associated with susceptibility to developing multiple sclerosis, greatly regulates a gene known as ANKRD55.
Children with and without multiple sclerosis have differences in gut bacteria
In a recent study, children with multiple sclerosis had differences in the abundance of specific gut bacteria than children without the disease.
Rituximab is superior to fingolimod for certain patients with multiple sclerosis
A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.

Related Multiple Sclerosis Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".